A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in patients with mild to moderate Alzheimer's Disease who are Apolopoprotien E4 epsilon4 Carriers

Grants and Contracts Details

StatusFinished
Effective start/end date7/1/0811/30/10

Funding

  • Elan Pharmaceuticals PLC: $128,300.00